CA2888805C - Methods and compositions for promoting axon regeneration and nerve function - Google Patents
Methods and compositions for promoting axon regeneration and nerve function Download PDFInfo
- Publication number
- CA2888805C CA2888805C CA2888805A CA2888805A CA2888805C CA 2888805 C CA2888805 C CA 2888805C CA 2888805 A CA2888805 A CA 2888805A CA 2888805 A CA2888805 A CA 2888805A CA 2888805 C CA2888805 C CA 2888805C
- Authority
- CA
- Canada
- Prior art keywords
- nec
- related compound
- neuron
- inhibitor
- necrostatin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000003050 axon Anatomy 0.000 title claims abstract description 83
- 238000000034 method Methods 0.000 title claims abstract description 81
- 230000008929 regeneration Effects 0.000 title claims abstract description 61
- 238000011069 regeneration method Methods 0.000 title claims abstract description 61
- 230000001737 promoting effect Effects 0.000 title claims abstract description 30
- 210000005036 nerve Anatomy 0.000 title abstract description 31
- 239000000203 mixture Substances 0.000 title description 33
- 210000002569 neuron Anatomy 0.000 claims abstract description 96
- 210000003169 central nervous system Anatomy 0.000 claims abstract description 81
- 208000020431 spinal cord injury Diseases 0.000 claims abstract description 22
- 230000007850 degeneration Effects 0.000 claims abstract description 8
- 208000024891 symptom Diseases 0.000 claims abstract description 6
- TXUWMXQFNYDOEZ-UHFFFAOYSA-N 5-(1H-indol-3-ylmethyl)-3-methyl-2-sulfanylidene-4-imidazolidinone Chemical compound O=C1N(C)C(=S)NC1CC1=CNC2=CC=CC=C12 TXUWMXQFNYDOEZ-UHFFFAOYSA-N 0.000 claims description 176
- 150000001875 compounds Chemical class 0.000 claims description 81
- 101150071716 PCSK1 gene Proteins 0.000 claims description 69
- 125000000217 alkyl group Chemical group 0.000 claims description 61
- 229910052739 hydrogen Inorganic materials 0.000 claims description 58
- 229910052736 halogen Inorganic materials 0.000 claims description 55
- 150000002367 halogens Chemical class 0.000 claims description 55
- 239000001257 hydrogen Substances 0.000 claims description 54
- 150000003839 salts Chemical class 0.000 claims description 54
- 150000002148 esters Chemical class 0.000 claims description 47
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 45
- 229940002612 prodrug Drugs 0.000 claims description 39
- 239000000651 prodrug Substances 0.000 claims description 39
- 229940127255 pan-caspase inhibitor Drugs 0.000 claims description 34
- 229940123169 Caspase inhibitor Drugs 0.000 claims description 23
- 125000003545 alkoxy group Chemical group 0.000 claims description 16
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 12
- SCVHJVCATBPIHN-SJCJKPOMSA-N (3s)-3-[[(2s)-2-[[2-(2-tert-butylanilino)-2-oxoacetyl]amino]propanoyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid Chemical compound N([C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)COC=1C(=C(F)C=C(F)C=1F)F)C(=O)C(=O)NC1=CC=CC=C1C(C)(C)C SCVHJVCATBPIHN-SJCJKPOMSA-N 0.000 claims description 11
- 229950000234 emricasan Drugs 0.000 claims description 11
- 210000002161 motor neuron Anatomy 0.000 claims description 10
- 230000000472 traumatic effect Effects 0.000 claims description 7
- 210000001044 sensory neuron Anatomy 0.000 claims description 6
- 230000002490 cerebral effect Effects 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- MIFGOLAMNLSLGH-QOKNQOGYSA-N Z-Val-Ala-Asp(OMe)-CH2F Chemical group COC(=O)C[C@@H](C(=O)CF)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)OCC1=CC=CC=C1 MIFGOLAMNLSLGH-QOKNQOGYSA-N 0.000 claims description 4
- 210000003618 cortical neuron Anatomy 0.000 claims description 4
- 210000004295 hippocampal neuron Anatomy 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 210000001259 mesencephalon Anatomy 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 238000007910 systemic administration Methods 0.000 claims description 2
- 150000002431 hydrogen Chemical group 0.000 claims 1
- 210000001176 projection neuron Anatomy 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 abstract description 98
- 230000017074 necrotic cell death Effects 0.000 abstract description 75
- 229940088872 Apoptosis inhibitor Drugs 0.000 abstract description 66
- 239000000158 apoptosis inhibitor Substances 0.000 abstract description 66
- 208000027418 Wounds and injury Diseases 0.000 abstract description 41
- 208000014674 injury Diseases 0.000 abstract description 41
- 230000006378 damage Effects 0.000 abstract description 40
- 208000015114 central nervous system disease Diseases 0.000 abstract description 28
- 208000029028 brain injury Diseases 0.000 abstract description 9
- 210000004556 brain Anatomy 0.000 abstract description 6
- 206010028851 Necrosis Diseases 0.000 description 71
- -1 e.g. Chemical compound 0.000 description 63
- 125000003118 aryl group Chemical group 0.000 description 35
- 239000003814 drug Substances 0.000 description 32
- 230000006870 function Effects 0.000 description 32
- 125000000623 heterocyclic group Chemical group 0.000 description 32
- 101001109145 Homo sapiens Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 description 28
- 102100022501 Receptor-interacting serine/threonine-protein kinase 1 Human genes 0.000 description 28
- 125000001072 heteroaryl group Chemical group 0.000 description 28
- 230000000694 effects Effects 0.000 description 24
- 102000011727 Caspases Human genes 0.000 description 21
- 108010076667 Caspases Proteins 0.000 description 21
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 21
- 125000003710 aryl alkyl group Chemical group 0.000 description 20
- 125000003107 substituted aryl group Chemical group 0.000 description 20
- 238000011282 treatment Methods 0.000 description 18
- 102100033729 Receptor-interacting serine/threonine-protein kinase 3 Human genes 0.000 description 17
- 101710138585 Receptor-interacting serine/threonine-protein kinase 3 Proteins 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 17
- 125000004093 cyano group Chemical group *C#N 0.000 description 16
- 210000001328 optic nerve Anatomy 0.000 description 16
- 230000006907 apoptotic process Effects 0.000 description 15
- 125000000753 cycloalkyl group Chemical group 0.000 description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 230000035899 viability Effects 0.000 description 14
- SMJGLNVGTJLIRV-KBEFMPHXSA-N (5z)-5-[[5-(4-fluorophenyl)-1h-pyrazol-4-yl]methylidene]-2-imino-3-(1,3-thiazol-2-yl)-1,3-thiazolidin-4-one Chemical compound C1=CC(F)=CC=C1C1=C(\C=C/2C(N(C(=N)S\2)C=2SC=CN=2)=O)C=NN1 SMJGLNVGTJLIRV-KBEFMPHXSA-N 0.000 description 13
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 12
- 229940043355 kinase inhibitor Drugs 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 210000003205 muscle Anatomy 0.000 description 12
- OVRPUVGBRNDNAS-VIFPVBQESA-N n-[(1s)-1-(2-chloro-6-fluorophenyl)ethyl]-5-cyano-1-methylpyrrole-2-carboxamide Chemical compound N([C@@H](C)C=1C(=CC=CC=1F)Cl)C(=O)C1=CC=C(C#N)N1C OVRPUVGBRNDNAS-VIFPVBQESA-N 0.000 description 12
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 12
- 230000030833 cell death Effects 0.000 description 11
- 239000000460 chlorine Substances 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- 208000006011 Stroke Diseases 0.000 description 10
- 230000003376 axonal effect Effects 0.000 description 10
- 229910052801 chlorine Inorganic materials 0.000 description 10
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 9
- 125000004475 heteroaralkyl group Chemical group 0.000 description 9
- 210000003994 retinal ganglion cell Anatomy 0.000 description 9
- VGONMECBFMCKBS-UHFFFAOYSA-N 2-[[3-(4-methoxyphenyl)-4-oxo-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-2-yl]sulfanyl]acetonitrile Chemical compound C1=CC(OC)=CC=C1N1C(=O)C(C=2CCCCC=2S2)=C2N=C1SCC#N VGONMECBFMCKBS-UHFFFAOYSA-N 0.000 description 8
- 108091007065 BIRCs Proteins 0.000 description 8
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 8
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 8
- 102000004091 Caspase-8 Human genes 0.000 description 8
- 108090000538 Caspase-8 Proteins 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 8
- 102000055031 Inhibitor of Apoptosis Proteins Human genes 0.000 description 8
- 108091000080 Phosphotransferase Proteins 0.000 description 8
- 125000003342 alkenyl group Chemical group 0.000 description 8
- 230000007659 motor function Effects 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 102000020233 phosphotransferase Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 230000037152 sensory function Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 description 7
- 208000024827 Alzheimer disease Diseases 0.000 description 7
- 108090000397 Caspase 3 Proteins 0.000 description 7
- 102100029855 Caspase-3 Human genes 0.000 description 7
- 101150045055 PCSK2 gene Proteins 0.000 description 7
- 208000018737 Parkinson disease Diseases 0.000 description 7
- 125000002252 acyl group Chemical group 0.000 description 7
- 125000000304 alkynyl group Chemical group 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 229940124530 sulfonamide Drugs 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 101100044298 Drosophila melanogaster fand gene Proteins 0.000 description 6
- 101150064015 FAS gene Proteins 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 101150050741 PCSK4 gene Proteins 0.000 description 6
- 101100335198 Pneumocystis carinii fol1 gene Proteins 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 102100040247 Tumor necrosis factor Human genes 0.000 description 6
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 6
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 6
- 230000003920 cognitive function Effects 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 230000021597 necroptosis Effects 0.000 description 6
- 108010040003 polyglutamine Proteins 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 210000000278 spinal cord Anatomy 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 5
- 108090000567 Caspase 7 Proteins 0.000 description 5
- 102100038902 Caspase-7 Human genes 0.000 description 5
- 102000004039 Caspase-9 Human genes 0.000 description 5
- 108090000566 Caspase-9 Proteins 0.000 description 5
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 5
- 208000025962 Crush injury Diseases 0.000 description 5
- 102000029797 Prion Human genes 0.000 description 5
- 108091000054 Prion Proteins 0.000 description 5
- 108010002687 Survivin Proteins 0.000 description 5
- 125000003368 amide group Chemical group 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 230000005775 apoptotic pathway Effects 0.000 description 5
- 125000002837 carbocyclic group Chemical group 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 210000005056 cell body Anatomy 0.000 description 5
- 238000011284 combination treatment Methods 0.000 description 5
- 229910052731 fluorine Inorganic materials 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 150000003456 sulfonamides Chemical class 0.000 description 5
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 4
- UMBVAPCONCILTL-MRHIQRDNSA-N Ac-Asp-Glu-Val-Asp-H Chemical compound OC(=O)C[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(C)=O UMBVAPCONCILTL-MRHIQRDNSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 108010049207 Death Domain Receptors Proteins 0.000 description 4
- 102000009058 Death Domain Receptors Human genes 0.000 description 4
- 206010012289 Dementia Diseases 0.000 description 4
- 102100033189 Diablo IAP-binding mitochondrial protein Human genes 0.000 description 4
- 101710101225 Diablo IAP-binding mitochondrial protein Proteins 0.000 description 4
- 101710156605 Diablo homolog, mitochondrial Proteins 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 101710136259 E3 ubiquitin-protein ligase XIAP Proteins 0.000 description 4
- 108010039471 Fas Ligand Protein Proteins 0.000 description 4
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 4
- 241000764238 Isis Species 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 108091027967 Small hairpin RNA Proteins 0.000 description 4
- 208000030886 Traumatic Brain injury Diseases 0.000 description 4
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 4
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 4
- 102000050257 X-Linked Inhibitor of Apoptosis Human genes 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 125000004442 acylamino group Chemical group 0.000 description 4
- 125000002947 alkylene group Chemical group 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 238000011990 functional testing Methods 0.000 description 4
- 125000005549 heteroarylene group Chemical group 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 4
- 238000005417 image-selected in vivo spectroscopy Methods 0.000 description 4
- 125000001841 imino group Chemical group [H]N=* 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 238000012739 integrated shape imaging system Methods 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 150000002576 ketones Chemical class 0.000 description 4
- 201000010901 lateral sclerosis Diseases 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 208000005264 motor neuron disease Diseases 0.000 description 4
- 208000015122 neurodegenerative disease Diseases 0.000 description 4
- 230000000626 neurodegenerative effect Effects 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 210000001525 retina Anatomy 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 4
- 230000008093 supporting effect Effects 0.000 description 4
- 230000009529 traumatic brain injury Effects 0.000 description 4
- WIKGAEMMNQTUGL-SNVBAGLBSA-N (5r)-5-[(7-chloro-1h-indol-3-yl)methyl]-3-methylimidazolidine-2,4-dione Chemical compound O=C1N(C)C(=O)N[C@@H]1CC1=CNC2=C(Cl)C=CC=C12 WIKGAEMMNQTUGL-SNVBAGLBSA-N 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 108020005544 Antisense RNA Proteins 0.000 description 3
- 101100347605 Arabidopsis thaliana VIII-A gene Proteins 0.000 description 3
- 201000006474 Brain Ischemia Diseases 0.000 description 3
- 229940124101 Caspase 3 inhibitor Drugs 0.000 description 3
- 102100035904 Caspase-1 Human genes 0.000 description 3
- 108090000426 Caspase-1 Proteins 0.000 description 3
- 102100038916 Caspase-5 Human genes 0.000 description 3
- 101710090333 Caspase-5 Proteins 0.000 description 3
- 206010008120 Cerebral ischaemia Diseases 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 3
- 206010067889 Dementia with Lewy bodies Diseases 0.000 description 3
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 3
- 208000013171 Fahr disease Diseases 0.000 description 3
- 201000011240 Frontotemporal dementia Diseases 0.000 description 3
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 3
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 3
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 3
- 201000002832 Lewy body dementia Diseases 0.000 description 3
- 208000008948 Menkes Kinky Hair Syndrome Diseases 0.000 description 3
- 208000012583 Menkes disease Diseases 0.000 description 3
- 208000030768 Optic nerve injury Diseases 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 3
- 208000018839 Wilson disease Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 125000004414 alkyl thio group Chemical group 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 230000028600 axonogenesis Effects 0.000 description 3
- 150000001540 azides Chemical class 0.000 description 3
- 201000002922 basal ganglia calcification Diseases 0.000 description 3
- 210000001084 basket cell Anatomy 0.000 description 3
- 208000016791 bilateral striopallidodentate calcinosis Diseases 0.000 description 3
- 210000000133 brain stem Anatomy 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 125000005518 carboxamido group Chemical group 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 206010008118 cerebral infarction Diseases 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 125000000392 cycloalkenyl group Chemical group 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 150000002430 hydrocarbons Chemical class 0.000 description 3
- 210000001153 interneuron Anatomy 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 230000003137 locomotive effect Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 230000001338 necrotic effect Effects 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 230000016273 neuron death Effects 0.000 description 3
- 210000003463 organelle Anatomy 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 229920000155 polyglutamine Polymers 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000001172 regenerating effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 125000000547 substituted alkyl group Chemical group 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 3
- 229920002554 vinyl polymer Polymers 0.000 description 3
- FKJMFCOMZYPWCO-HNNXBMFYSA-N (3s)-5-(2,6-dichlorobenzoyl)oxy-4-oxo-3-(phenylmethoxycarbonylamino)pentanoic acid Chemical compound N([C@@H](CC(=O)O)C(=O)COC(=O)C=1C(=CC=CC=1Cl)Cl)C(=O)OCC1=CC=CC=C1 FKJMFCOMZYPWCO-HNNXBMFYSA-N 0.000 description 2
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 description 2
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 2
- HKIPCXRNASWFRU-UHFFFAOYSA-N 1,3-difluoropropan-2-one Chemical compound FCC(=O)CF HKIPCXRNASWFRU-UHFFFAOYSA-N 0.000 description 2
- QXGBVUBUQAGSCW-RXVVDRJESA-N 1-[(3r,3ar)-8-methoxy-3-(4-methoxyphenyl)-3,3a,4,5-tetrahydrobenzo[g]indazol-2-yl]ethanone Chemical compound C1=CC(OC)=CC=C1[C@@H]1N(C(C)=O)N=C2C3=CC(OC)=CC=C3CC[C@@H]21 QXGBVUBUQAGSCW-RXVVDRJESA-N 0.000 description 2
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 102000004018 Caspase 6 Human genes 0.000 description 2
- 108090000425 Caspase 6 Proteins 0.000 description 2
- 229940122396 Caspase 9 inhibitor Drugs 0.000 description 2
- 102000004046 Caspase-2 Human genes 0.000 description 2
- 108090000552 Caspase-2 Proteins 0.000 description 2
- 102100025597 Caspase-4 Human genes 0.000 description 2
- 101710090338 Caspase-4 Proteins 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- 102400000686 Endothelin-1 Human genes 0.000 description 2
- 101800004490 Endothelin-1 Proteins 0.000 description 2
- 108010008165 Etanercept Proteins 0.000 description 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 101000597785 Homo sapiens Tumor necrosis factor receptor superfamily member 6B Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 208000001089 Multiple system atrophy Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 102000002808 Pituitary adenylate cyclase-activating polypeptide Human genes 0.000 description 2
- 108010004684 Pituitary adenylate cyclase-activating polypeptide Proteins 0.000 description 2
- 108010003541 Platelet Activating Factor Proteins 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 108091030071 RNAI Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 2
- 108010000449 TNF-Related Apoptosis-Inducing Ligand Receptors Proteins 0.000 description 2
- 102000002259 TNF-Related Apoptosis-Inducing Ligand Receptors Human genes 0.000 description 2
- 102100024598 Tumor necrosis factor ligand superfamily member 10 Human genes 0.000 description 2
- 101710097160 Tumor necrosis factor ligand superfamily member 10 Proteins 0.000 description 2
- 102100035284 Tumor necrosis factor receptor superfamily member 6B Human genes 0.000 description 2
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 2
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 229920000392 Zymosan Polymers 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 229960002964 adalimumab Drugs 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000002567 autonomic effect Effects 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 229940123098 caspase 6 inhibitor Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 210000001787 dendrite Anatomy 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- IRSFLDGTOHBADP-UHFFFAOYSA-N embelin Chemical compound CCCCCCCCCCCC1=C(O)C(=O)C=C(O)C1=O IRSFLDGTOHBADP-UHFFFAOYSA-N 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 229960000403 etanercept Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000000763 evoking effect Effects 0.000 description 2
- 108010052621 fas Receptor Proteins 0.000 description 2
- 102000018823 fas Receptor Human genes 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- DVGHHMFBFOTGLM-UHFFFAOYSA-L fluorogold Chemical compound F[Au][Au]F DVGHHMFBFOTGLM-UHFFFAOYSA-L 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 210000004565 granule cell Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 125000004404 heteroalkyl group Chemical group 0.000 description 2
- 230000033444 hydroxylation Effects 0.000 description 2
- 238000005805 hydroxylation reaction Methods 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- MIFGOLAMNLSLGH-SXUUOERCSA-N methyl 5-fluoro-3-[[(2s)-2-[[(2s)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]propanoyl]amino]-4-oxopentanoate Chemical compound COC(=O)CC(C(=O)CF)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)OCC1=CC=CC=C1 MIFGOLAMNLSLGH-SXUUOERCSA-N 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 238000010984 neurological examination Methods 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 210000001428 peripheral nervous system Anatomy 0.000 description 2
- UFTCZKMBJOPXDM-XXFCQBPRSA-N pituitary adenylate cyclase-activating polypeptide Chemical compound C([C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 UFTCZKMBJOPXDM-XXFCQBPRSA-N 0.000 description 2
- 210000000063 presynaptic terminal Anatomy 0.000 description 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 210000002763 pyramidal cell Anatomy 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 230000007832 reinnervation Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229940069575 rompun Drugs 0.000 description 2
- 210000003786 sclera Anatomy 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 229940075439 smac mimetic Drugs 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- QYEFBJRXKKSABU-UHFFFAOYSA-N xylazine hydrochloride Chemical compound Cl.CC1=CC=CC(C)=C1NC1=NCCCS1 QYEFBJRXKKSABU-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- XYXYXSKSTZAEJW-VIFPVBQESA-N (2s)-2-(phenylmethoxycarbonylamino)butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)OCC1=CC=CC=C1 XYXYXSKSTZAEJW-VIFPVBQESA-N 0.000 description 1
- HBYDKJCHUAGGDW-VJARNRFFSA-N (3s)-3-[[(2s)-2-[[(2s)-2-[[(2s)-2-[acetyl(methyl)amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-4-oxobutanoic acid Chemical compound OC(=O)C[C@@H](C=O)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N(C)C(C)=O)CC1=CC=C(O)C=C1 HBYDKJCHUAGGDW-VJARNRFFSA-N 0.000 description 1
- LPIARALSGDVZEP-SJVNDZIOSA-N (3s)-3-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-4-oxobutanoic acid Chemical compound OC(=O)C[C@@H](C=O)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(C)=O)CC1=CC=C(O)C=C1 LPIARALSGDVZEP-SJVNDZIOSA-N 0.000 description 1
- UOUBHJRCKHLGFB-DGJUNBOTSA-N (3s)-3-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-chloro-4-oxopentanoic acid Chemical compound OC(=O)C[C@@H](C(=O)CCl)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(C)=O)CC1=CC=C(O)C=C1 UOUBHJRCKHLGFB-DGJUNBOTSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- SUUHZYLYARUNIA-YEWWUXTCSA-N (3s)-5-fluoro-3-[[(2s)-2-[[(2s)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]propanoyl]amino]-4-oxopentanoic acid Chemical compound OC(=O)C[C@@H](C(=O)CF)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)OCC1=CC=CC=C1 SUUHZYLYARUNIA-YEWWUXTCSA-N 0.000 description 1
- ATNOUPFYBMVFLD-RSLFNQERSA-N (4s)-4-[[(2s)-2-acetamido-3-carboxypropanoyl]amino]-5-[[(2s)-1-[[(2s)-1-carboxy-4-chloro-3-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoic acid Chemical compound OC(=O)C[C@@H](C(=O)CCl)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(C)=O ATNOUPFYBMVFLD-RSLFNQERSA-N 0.000 description 1
- AXTKTZHLZLOIIO-PBEPODTISA-N (4s)-4-[[(2s,3s)-2-acetamido-3-methylpentanoyl]amino]-5-[[(2s,3r)-1-[[(2s)-1-carboxy-3-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C=O AXTKTZHLZLOIIO-PBEPODTISA-N 0.000 description 1
- TVTYMGFOGZRIHG-XUXIUFHCSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-1-carboxy-3-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound OC(=O)C[C@@H](C=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(C)=O TVTYMGFOGZRIHG-XUXIUFHCSA-N 0.000 description 1
- CTXDBLYOEUERAT-VUVYEONESA-N (4s)-5-[[(2s,3r)-1-[[(2s)-1-carboxy-4-fluoro-3-oxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-[[(2s,3s)-3-methyl-2-(phenylmethoxycarbonylamino)pentanoyl]amino]-5-oxopentanoic acid Chemical compound OC(=O)C[C@@H](C(=O)CF)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)OCC1=CC=CC=C1 CTXDBLYOEUERAT-VUVYEONESA-N 0.000 description 1
- CXAGHAZMQSCAKJ-WAHHBDPQSA-N (4s,7s)-n-[(2r,3s)-2-ethoxy-5-oxooxolan-3-yl]-7-(isoquinoline-1-carbonylamino)-6,10-dioxo-2,3,4,7,8,9-hexahydro-1h-pyridazino[1,2-a]diazepine-4-carboxamide Chemical compound CCO[C@@H]1OC(=O)C[C@@H]1NC(=O)[C@H]1N(C(=O)[C@H](CCC2=O)NC(=O)C=3C4=CC=CC=C4C=CN=3)N2CCC1 CXAGHAZMQSCAKJ-WAHHBDPQSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 1
- WEEFNMFMNMASJY-UHFFFAOYSA-M 1,2-dimethoxy-12-methyl-[1,3]benzodioxolo[5,6-c]phenanthridin-12-ium;chloride Chemical compound [Cl-].C1=C2OCOC2=CC2=CC=C3C4=CC=C(OC)C(OC)=C4C=[N+](C)C3=C21 WEEFNMFMNMASJY-UHFFFAOYSA-M 0.000 description 1
- RFBVBRVVOPAAFS-UHFFFAOYSA-N 2,2-bis(hydroxymethyl)-1-azabicyclo[2.2.2]octan-3-one Chemical compound C1CC2CCN1C(CO)(CO)C2=O RFBVBRVVOPAAFS-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
- TYJOQICPGZGYDT-UHFFFAOYSA-N 4-methylsulfonylbenzenesulfonyl chloride Chemical compound CS(=O)(=O)C1=CC=C(S(Cl)(=O)=O)C=C1 TYJOQICPGZGYDT-UHFFFAOYSA-N 0.000 description 1
- SUUHZYLYARUNIA-LWSHRDBSSA-N 5-fluoro-3-[[(2s)-2-[[(2s)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]propanoyl]amino]-4-oxopentanoic acid Chemical compound OC(=O)CC(C(=O)CF)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)OCC1=CC=CC=C1 SUUHZYLYARUNIA-LWSHRDBSSA-N 0.000 description 1
- LYBWGROBJJXCJJ-VYIIXAMBSA-N 5-fluoro-3-[[(2s)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]-4-oxopentanoic acid Chemical compound OC(=O)CC(C(=O)CF)NC(=O)[C@H](C(C)C)NC(=O)OCC1=CC=CC=C1 LYBWGROBJJXCJJ-VYIIXAMBSA-N 0.000 description 1
- 125000004008 6 membered carbocyclic group Chemical group 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical class NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical group OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 102220533139 Baculoviral IAP repeat-containing protein 5_T34A_mutation Human genes 0.000 description 1
- 108010079882 Bax protein (53-86) Proteins 0.000 description 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 1
- KAJYHKRSEVHEGX-HCQSHQBASA-N C1[C@@]([N+]([O-])=O)(C)[C@@H](NC(=O)OC)[C@@H](C)O[C@H]1O[C@@H]1C(/C)=C/[C@@H]2[C@@H](O)CC(C=O)=CC2(C2=O)OC(O)=C2C(=O)[C@@]2(C)[C@@H]3[C@@H](C)C[C@H](C)[C@H](O[C@@H]4O[C@@H](C)[C@H](OC(C)=O)[C@H](O[C@@H]5O[C@@H](C)[C@H](O[C@@H]6O[C@@H](C)[C@H](O[C@@H]7O[C@@H](C)[C@H](O)CC7)[C@H](O)C6)CC5)C4)[C@H]3C=C[C@H]2\C(C)=C/C1 Chemical class C1[C@@]([N+]([O-])=O)(C)[C@@H](NC(=O)OC)[C@@H](C)O[C@H]1O[C@@H]1C(/C)=C/[C@@H]2[C@@H](O)CC(C=O)=CC2(C2=O)OC(O)=C2C(=O)[C@@]2(C)[C@@H]3[C@@H](C)C[C@H](C)[C@H](O[C@@H]4O[C@@H](C)[C@H](OC(C)=O)[C@H](O[C@@H]5O[C@@H](C)[C@H](O[C@@H]6O[C@@H](C)[C@H](O[C@@H]7O[C@@H](C)[C@H](O)CC7)[C@H](O)C6)CC5)C4)[C@H]3C=C[C@H]2\C(C)=C/C1 KAJYHKRSEVHEGX-HCQSHQBASA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229940122728 Caspase 2 inhibitor Drugs 0.000 description 1
- 229940123063 Caspase 4 inhibitor Drugs 0.000 description 1
- 229940100513 Caspase 8 inhibitor Drugs 0.000 description 1
- 102000004068 Caspase-10 Human genes 0.000 description 1
- 108090000572 Caspase-10 Proteins 0.000 description 1
- 102000004066 Caspase-12 Human genes 0.000 description 1
- 108090000570 Caspase-12 Proteins 0.000 description 1
- 102000004958 Caspase-14 Human genes 0.000 description 1
- 108090001132 Caspase-14 Proteins 0.000 description 1
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 description 1
- LLEJIEBFSOEYIV-UHFFFAOYSA-N Chelerythrine Natural products C1=C2OCOC2=CC2=CC=C3C4=CC=C(OC)C(OC)=C4C=[N+](C)C3=C21 LLEJIEBFSOEYIV-UHFFFAOYSA-N 0.000 description 1
- 206010008786 Choroidal haemorrhage Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 108010056643 Corticotropin-Releasing Hormone Receptors Proteins 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- 102000010170 Death domains Human genes 0.000 description 1
- 108050001718 Death domains Proteins 0.000 description 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
- RATMHCJTVBHJSU-UHFFFAOYSA-N Dihydrochelerythrine Natural products C1=C2OCOC2=CC2=C(N(C)C(O)C=3C4=CC=C(C=3OC)OC)C4=CC=C21 RATMHCJTVBHJSU-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000024412 Friedreich ataxia Diseases 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 101000643956 Homo sapiens Cytochrome b-c1 complex subunit Rieske, mitochondrial Proteins 0.000 description 1
- 101001099199 Homo sapiens RalA-binding protein 1 Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- OWIKHYCFFJSOEH-UHFFFAOYSA-N Isocyanic acid Chemical compound N=C=O OWIKHYCFFJSOEH-UHFFFAOYSA-N 0.000 description 1
- WZNJWVWKTVETCG-YFKPBYRVSA-N L-mimosine Chemical compound OC(=O)[C@@H](N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-YFKPBYRVSA-N 0.000 description 1
- 101000933115 Mus musculus Caspase-4 Proteins 0.000 description 1
- 206010029174 Nerve compression Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- BDUHCSBCVGXTJM-IZLXSDGUSA-N Nutlin-3 Chemical compound CC(C)OC1=CC(OC)=CC=C1C1=N[C@H](C=2C=CC(Cl)=CC=2)[C@H](C=2C=CC(Cl)=CC=2)N1C(=O)N1CC(=O)NCC1 BDUHCSBCVGXTJM-IZLXSDGUSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010079855 Peptide Aptamers Proteins 0.000 description 1
- 102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 101150008375 Pou4f1 gene Proteins 0.000 description 1
- 101100528525 Prochlorococcus marinus (strain SARG / CCMP1375 / SS120) rnc gene Proteins 0.000 description 1
- 108010065954 SMAC peptide Proteins 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 208000020339 Spinal injury Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 206010048327 Supranuclear palsy Diseases 0.000 description 1
- 108010006877 Tacrolimus Binding Protein 1A Proteins 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- GBJVAVGBSGRRKN-JYEBCORGSA-N Z-DEVD-FMK Chemical compound COC(=O)C[C@@H](C(=O)CF)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)OC)NC(=O)[C@H](CC(=O)OC)NC(=O)OCC1=CC=CC=C1 GBJVAVGBSGRRKN-JYEBCORGSA-N 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000004422 alkyl sulphonamide group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- JKOQGQFVAUAYPM-UHFFFAOYSA-N amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 description 1
- 229960001097 amifostine Drugs 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- UIFFUZWRFRDZJC-SBOOETFBSA-N antimycin A Chemical class C[C@H]1OC(=O)[C@H](CCCCCC)[C@@H](OC(=O)CC(C)C)[C@H](C)OC(=O)[C@H]1NC(=O)C1=CC=CC(NC=O)=C1O UIFFUZWRFRDZJC-SBOOETFBSA-N 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
- 125000004421 aryl sulphonamide group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- MNFORVFSTILPAW-UHFFFAOYSA-N azetidin-2-one Chemical class O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 description 1
- MEPJLBXTZZGXOV-UHFFFAOYSA-N azidocarbamic acid Chemical compound OC(=O)NN=[N+]=[N-] MEPJLBXTZZGXOV-UHFFFAOYSA-N 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 229960004530 benazepril Drugs 0.000 description 1
- 108010071933 benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone Proteins 0.000 description 1
- 108010088607 benzoylcarbonyl-valyl-aspartyl-valyl-alanyl-aspartyl-fluoromethyl ketone Proteins 0.000 description 1
- 108010072383 benzyloxycarbonyl aspartyl-glutamyl-valyl-aspartyl-chloromethyl ketone Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 125000004057 biotinyl group Chemical group [H]N1C(=O)N([H])[C@]2([H])[C@@]([H])(SC([H])([H])[C@]12[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 108010018550 caspase 13 Proteins 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 150000001789 chalcones Chemical class 0.000 description 1
- 235000005513 chalcones Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000010428 chromatin condensation Effects 0.000 description 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 229920006237 degradable polymer Polymers 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 125000005303 dithiazolyl group Chemical group S1SNC(=C1)* 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 210000001951 dura mater Anatomy 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003099 femoral nerve Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 210000003652 golgi cell Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000008675 hereditary spastic paraplegia Diseases 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 210000002287 horizontal cell Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 108010058929 immunocasp-6 Proteins 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000008011 inorganic excipient Substances 0.000 description 1
- 108010027775 interleukin-1beta-converting enzyme inhibitor Proteins 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 229940039412 ketalar Drugs 0.000 description 1
- 229960004184 ketamine hydrochloride Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 238000002684 laminectomy Methods 0.000 description 1
- 230000008449 language Effects 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 229950001869 mapatumumab Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 125000005395 methacrylic acid group Chemical class 0.000 description 1
- QFITYVNVMNJELE-TUFLPTIASA-N methyl (3s)-3-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-4-methoxy-4-oxo-2-(phenylmethoxycarbonylamino)butanoyl]amino]-5-oxopentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-fluoro-4-oxopentanoate Chemical compound COC(=O)C[C@@H](C(=O)CF)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(=O)OC)NC(=O)OCC1=CC=CC=C1 QFITYVNVMNJELE-TUFLPTIASA-N 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 229950002289 mimosine Drugs 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000003007 myelin sheath Anatomy 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000032405 negative regulation of neuron apoptotic process Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 230000009689 neuronal regeneration Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 229960000435 oblimersen Drugs 0.000 description 1
- MIMNFCVQODTQDP-NDLVEFNKSA-N oblimersen Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(S)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 MIMNFCVQODTQDP-NDLVEFNKSA-N 0.000 description 1
- 210000001636 ophthalmic artery Anatomy 0.000 description 1
- 239000008012 organic excipient Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000005475 oxolanyl group Chemical group 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- HAGVCKULCLQGRF-UHFFFAOYSA-N pifithrin Chemical compound [Br-].C1=CC(C)=CC=C1C(=O)CN1[C+](N)SC2=C1CCCC2 HAGVCKULCLQGRF-UHFFFAOYSA-N 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 210000000449 purkinje cell Anatomy 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000005551 pyridylene group Chemical group 0.000 description 1
- 150000004040 pyrrolidinones Chemical class 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000004116 schwann cell Anatomy 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000001148 spastic effect Effects 0.000 description 1
- 210000001032 spinal nerve Anatomy 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 150000008053 sultones Chemical class 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 210000002504 synaptic vesicle Anatomy 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
- 125000001166 thiolanyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 1
- 229960004699 valsartan Drugs 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000011816 wild-type C57Bl6 mouse Methods 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960004175 xylazine hydrochloride Drugs 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161550191P | 2011-10-21 | 2011-10-21 | |
| US61/550,191 | 2011-10-21 | ||
| PCT/US2012/061324 WO2013059791A2 (en) | 2011-10-21 | 2012-10-22 | Methods and compositions for promoting axon regeneration and nerve function |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2888805A1 CA2888805A1 (en) | 2013-04-25 |
| CA2888805C true CA2888805C (en) | 2020-07-14 |
Family
ID=47116494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2888805A Expired - Fee Related CA2888805C (en) | 2011-10-21 | 2012-10-22 | Methods and compositions for promoting axon regeneration and nerve function |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20140357570A1 (enExample) |
| EP (1) | EP2773341A2 (enExample) |
| JP (3) | JP6254090B2 (enExample) |
| CA (1) | CA2888805C (enExample) |
| HK (1) | HK1203044A1 (enExample) |
| WO (1) | WO2013059791A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2749634C1 (ru) * | 2020-11-30 | 2021-06-16 | Федеральное государственное бюджетное учреждение "Российский научный центр радиологии и хирургических технологий имени академика А.М. Гранова" Министерства здравоохранения Российской Федерации | Способ моделирования лечения больных с двигательными и висцеральными расстройствами на лабораторных животных. |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011133964A2 (en) | 2010-04-23 | 2011-10-27 | Massachusetts Eye And Ear Infirmary | Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells |
| WO2012061045A2 (en) | 2010-11-01 | 2012-05-10 | Massachusetts Eye And Ear Infirmary | Methods and compositions for preserving retinal ganglion cells |
| JP6254090B2 (ja) | 2011-10-21 | 2017-12-27 | マサチューセッツ・アイ・アンド・イア・インファーマリー | 軸索再生および神経機能を促進するための方法および組成物 |
| TWI648273B (zh) | 2013-02-15 | 2019-01-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類（三） |
| CL2013003785A1 (es) * | 2013-12-30 | 2014-07-11 | Univ Pontificia Catolica Chile | Uso de necrostatina-1 para el tratamiento de la degeneracion axonal inducida por daños agudos y cronicos |
| WO2016094846A1 (en) | 2014-12-11 | 2016-06-16 | President And Fellows Of Harvard College | Inhibitors of cellular necrosis and related methods |
| EP3265440A1 (en) | 2015-03-06 | 2018-01-10 | Concert Pharmaceuticals Inc. | Deuterated emricasan |
| TWI788830B (zh) | 2015-07-02 | 2023-01-01 | 瑞士商赫孚孟拉羅股份公司 | 雙環內醯胺及其使用方法 |
| SG10201913587WA (en) | 2016-02-05 | 2020-02-27 | Denali Therapeutics Inc | Inhibitors of receptor-interacting protein kinase 1 |
| EP3526219B1 (en) | 2016-10-17 | 2021-12-15 | F. Hoffmann-La Roche AG | Bicyclic pyridone lactams and methods of use thereof |
| DK3552017T3 (da) | 2016-12-09 | 2022-05-16 | Denali Therapeutics Inc | Forbindelser, der er anvendelige som ripk1-inhibitorer |
| US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| JP7594441B2 (ja) * | 2017-12-31 | 2024-12-04 | エバーグリーン バイオサイエンシズ | 凍結保存用組成物およびその使用方法 |
| JP7398391B2 (ja) | 2018-04-20 | 2023-12-14 | エフ． ホフマン－ラ ロシュ アーゲー | Ｎ－［４－オキソ－２，３－ジヒドロ－１，５－ベンズオキサゼピン－３－イル］－５，６－ジヒドロ－４Ｈ－ピロロ［１，２－ｂ］ピラゾール－２－カルボキサミド誘導体及び例えば過敏性腸症候群（ＩＢＳ）を処置するためのＲＩＰ１キナーゼ阻害剤としての関連化合物 |
| WO2023137035A1 (en) | 2022-01-12 | 2023-07-20 | Denali Therapeutics Inc. | Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide |
| WO2025165088A1 (ko) * | 2024-01-31 | 2025-08-07 | (주)노보메디슨 | 캐스파제 저해제의 용도 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
| US5725493A (en) | 1994-12-12 | 1998-03-10 | Avery; Robert Logan | Intravitreal medicine delivery |
| US6299895B1 (en) | 1997-03-24 | 2001-10-09 | Neurotech S.A. | Device and method for treating ophthalmic diseases |
| CA2271783C (en) | 1996-11-20 | 2013-04-16 | Yale University | Survivin, a protein that inhibits cellular apoptosis, and its modulation |
| EP1154691A4 (en) | 1999-01-05 | 2004-07-07 | Massachusetts Eye & Ear Infirm | TARGETED ADMINISTRATION OF REGULATED RELEASE MEDICINE TO RETINA AND CHOROID THROUGH SCLEROTIC |
| WO2001028493A2 (en) * | 1999-10-15 | 2001-04-26 | President And Fellows Of Harvard College | Small molecule inhibitors of necrosis |
| ATE414494T1 (de) | 1999-10-21 | 2008-12-15 | Alcon Inc | Medikamentenzuführeinrichtung |
| US6416777B1 (en) | 1999-10-21 | 2002-07-09 | Alcon Universal Ltd. | Ophthalmic drug delivery device |
| AU1920501A (en) | 1999-12-03 | 2001-06-12 | Alcon Universal Limited | The use of caspase 9 inhibitors to treat ocular neural pathology |
| US6375972B1 (en) | 2000-04-26 | 2002-04-23 | Control Delivery Systems, Inc. | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
| WO2002063959A1 (en) * | 2001-02-09 | 2002-08-22 | The Schepens Eye Research Institute | Methods and compositions for stimulating axon regeneration and prventing neuronal cell degeneration |
| WO2002089767A1 (en) | 2001-05-03 | 2002-11-14 | Massachusetts Eye And Ear Infirmary | Implantable drug delivery device and use thereof |
| AU2003209297A1 (en) | 2002-01-18 | 2003-09-02 | Massachusetts Eye And Ear Infirmary | Methods and compositions for preserving the viability of photoreceptor cells |
| US20050130877A1 (en) * | 2003-03-14 | 2005-06-16 | Children's Medical Center Corporation | Axon regeneration with PKC inhibitors |
| DK2384753T3 (en) * | 2003-08-29 | 2016-04-11 | Brigham & Womens Hospital | Hydantoin derivatives as inhibitors of cell necrosis |
| US8912144B2 (en) * | 2003-12-16 | 2014-12-16 | Children's Medical Center Corporation | Method for treating stroke via administration of NEP1-40 and inosine |
| US20070049565A1 (en) * | 2005-08-24 | 2007-03-01 | Neurotech Pharmaceuticals Co., Ltd. | Combination of cell necrosis inhibitor and lithium for treating neuronal death or neurological dysfunction |
| US20070298129A1 (en) | 2005-08-24 | 2007-12-27 | Neurotech Pharmaceuticals Co., Ltd. | Compounds and compositions for treating neuronal death or neurological dysfunction |
| JP2009521454A (ja) * | 2005-12-20 | 2009-06-04 | プレジデント・アンド・フエローズ・オブ・ハーバード・カレツジ | 化合物、スクリーニング、および処置方法 |
| CN101374860A (zh) | 2005-12-23 | 2009-02-25 | 技术转让合伙人公司 | 用作神经递质分泌抑制剂和肌肉松弛诱导物的合成肽 |
| EP2076134A4 (en) * | 2006-10-10 | 2020-07-29 | President and Fellows of Harvard College | COMPOUNDS, SCREENS, AND TREATMENT METHODS |
| US20090022570A1 (en) * | 2007-07-16 | 2009-01-22 | Joe David Craig | System, method and apparatus for feeding biomass into a pressurized vessel |
| CA2696349A1 (en) | 2007-08-15 | 2009-02-19 | President And Fellows Of Harvard College | Heterocyclic inhibitors of necroptosis |
| US20110190356A1 (en) * | 2008-08-19 | 2011-08-04 | Knopp Neurosciences Inc. | Compositions and Methods of Using (R)- Pramipexole |
| WO2010075290A1 (en) * | 2008-12-22 | 2010-07-01 | President And Fellows Of Harvard College | Unsaturated heterocyclic inhibitors of necroptosis |
| US7622106B1 (en) | 2009-03-06 | 2009-11-24 | Board Of Regents, The University Of Texas System | Necrosis assay |
| CA2783422A1 (en) | 2009-12-09 | 2011-06-16 | Sapporo Medical University | Method for producing superoxide, method for evaluating superoxide scavenging ability, device for producing superoxide, and device for evaluating superoxide scavenging ability |
| WO2011133964A2 (en) | 2010-04-23 | 2011-10-27 | Massachusetts Eye And Ear Infirmary | Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells |
| WO2012061045A2 (en) | 2010-11-01 | 2012-05-10 | Massachusetts Eye And Ear Infirmary | Methods and compositions for preserving retinal ganglion cells |
| JP6254090B2 (ja) | 2011-10-21 | 2017-12-27 | マサチューセッツ・アイ・アンド・イア・インファーマリー | 軸索再生および神経機能を促進するための方法および組成物 |
-
2012
- 2012-10-22 JP JP2014537360A patent/JP6254090B2/ja active Active
- 2012-10-22 US US14/352,960 patent/US20140357570A1/en not_active Abandoned
- 2012-10-22 CA CA2888805A patent/CA2888805C/en not_active Expired - Fee Related
- 2012-10-22 HK HK15102094.4A patent/HK1203044A1/xx unknown
- 2012-10-22 WO PCT/US2012/061324 patent/WO2013059791A2/en not_active Ceased
- 2012-10-22 EP EP12780381.5A patent/EP2773341A2/en not_active Withdrawn
-
2015
- 2015-11-02 US US14/930,501 patent/US10022419B2/en active Active
-
2017
- 2017-11-29 JP JP2017228601A patent/JP6560325B2/ja not_active Expired - Fee Related
-
2018
- 2018-06-22 US US16/015,947 patent/US10799552B2/en active Active
-
2019
- 2019-07-18 JP JP2019132740A patent/JP6861764B2/ja not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2749634C1 (ru) * | 2020-11-30 | 2021-06-16 | Федеральное государственное бюджетное учреждение "Российский научный центр радиологии и хирургических технологий имени академика А.М. Гранова" Министерства здравоохранения Российской Федерации | Способ моделирования лечения больных с двигательными и висцеральными расстройствами на лабораторных животных. |
Also Published As
| Publication number | Publication date |
|---|---|
| US20190117724A1 (en) | 2019-04-25 |
| JP6254090B2 (ja) | 2017-12-27 |
| US20140357570A1 (en) | 2014-12-04 |
| JP6560325B2 (ja) | 2019-08-14 |
| EP2773341A2 (en) | 2014-09-10 |
| WO2013059791A3 (en) | 2013-07-11 |
| JP2014530881A (ja) | 2014-11-20 |
| JP2019196381A (ja) | 2019-11-14 |
| JP6861764B2 (ja) | 2021-04-21 |
| US10799552B2 (en) | 2020-10-13 |
| US20160151442A1 (en) | 2016-06-02 |
| JP2018065838A (ja) | 2018-04-26 |
| US10022419B2 (en) | 2018-07-17 |
| WO2013059791A2 (en) | 2013-04-25 |
| CA2888805A1 (en) | 2013-04-25 |
| HK1203044A1 (en) | 2015-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10799552B2 (en) | Methods for treating diabetic neurotherapy | |
| JP7571171B2 (ja) | 翼状片を治療するための組成物及び方法 | |
| US10617735B2 (en) | Methods and compositions for preserving retinal ganglion cells | |
| AU2017202550B2 (en) | Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells | |
| JP5232678B2 (ja) | 新形成細胞の細胞消滅死を誘導する方法 | |
| ES2549955T3 (es) | Prevención de hipoglucemia en pacientes con diabetes mellitus de tipo 2 | |
| KR20100016140A (ko) | 가령 황반 변성의 예방 또는 치료제 | |
| KR20120129904A (ko) | 안내 혈관 신생 및/또는 안내 혈관 투과성 항진을 수반하는 질환의 예방 또는 치료를 위한 의약 | |
| JP2015521608A (ja) | 緑内障および他の変性眼疾患のヒトにおける失明の治療のためのインターバル療法 | |
| CN112513057A (zh) | 供在由衰老细胞引起或介导的状况的临床管理中使用和用于治疗癌症的作为Bcl家族拮抗剂的酰基氨基膦酸酯和酰基苄胺 | |
| TWI791440B (zh) | Dsg2-衍生肽 | |
| ES3064694T3 (en) | Gap junction modulators and their use for the treatment of age-related macular degeneration | |
| US11497793B2 (en) | Compositions and methods for treating glioblastoma | |
| CA3056878C (en) | Phospholidines that are bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer | |
| KR20210058586A (ko) | 실데나필 및 rock 저해제를 포함하는 뇌졸중 치료용 약학적 조성물 | |
| ES3062815T3 (en) | Compositions for treating aging-associated impairments using ccr3-inhibitors | |
| HK40069641A (en) | Compositions and methods for treating pterygium | |
| HK1143544A (en) | The use of substances for the treatment of loss of eyesight in humans with glaucoma and other degenerative eye diseases | |
| HK1256602B (en) | Compositions and methods for treating pterygium |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20171013 |
|
| MKLA | Lapsed |
Effective date: 20221024 |